secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001140361-26-000995
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics amends severance for CEO (12-18 mo) and 4 execs (6 mo) as of Jan 10, 2026
--------------------------------------------------------------------------------

- CEO Prashant Kohli gets 12 mo base salary (no CIC) or 18 mo base+target bonus (CIC) plus COBRA.
- Four other executives get 6 mo base salary (no CIC) or 6 mo base+target bonus (CIC) plus COBRA.
- Unvested equity forfeited on termination without Cause absent CIC; fully vests if terminated/resigned within 12 mo after CIC.
- Amendments effective January 10, 2026; prior severance terms superseded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126000995/0001140361-26-000995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126000995/ef20062691_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer